NO954880L - Cytidin deaminase - Google Patents

Cytidin deaminase

Info

Publication number
NO954880L
NO954880L NO954880A NO954880A NO954880L NO 954880 L NO954880 L NO 954880L NO 954880 A NO954880 A NO 954880A NO 954880 A NO954880 A NO 954880A NO 954880 L NO954880 L NO 954880L
Authority
NO
Norway
Prior art keywords
cytidine deaminase
cell proliferation
enhancers
blood
stem cells
Prior art date
Application number
NO954880A
Other languages
English (en)
Other versions
NO954880D0 (no
Inventor
Arne Boeyum
Original Assignee
Nycomed Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Pharma As filed Critical Nycomed Pharma As
Publication of NO954880D0 publication Critical patent/NO954880D0/no
Publication of NO954880L publication Critical patent/NO954880L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04005—Cytidine deaminase (3.5.4.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Denne oppfinnelsen relaterer til cytidin deaminase og dens forsterkere for bruk i celle- proliferasjon, spesielt hematopoese, og bruk av cytidin deaminase inhibitorer for å stimulere celle- proliferasjon, spesielt ved leukemiske forhold og til å mobilisere stamceller i blodet.
NO954880A 1993-06-01 1995-11-30 Cytidin deaminase NO954880L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939311252A GB9311252D0 (en) 1993-06-01 1993-06-01 Cell growth regualtors
PCT/GB1994/001190 WO1994027632A1 (en) 1993-06-01 1994-06-01 Cell growth regulators

Publications (2)

Publication Number Publication Date
NO954880D0 NO954880D0 (no) 1995-11-30
NO954880L true NO954880L (no) 1996-01-30

Family

ID=10736425

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954880A NO954880L (no) 1993-06-01 1995-11-30 Cytidin deaminase

Country Status (6)

Country Link
EP (1) EP0703787A1 (no)
JP (1) JPH08510385A (no)
AU (1) AU6803694A (no)
GB (1) GB9311252D0 (no)
NO (1) NO954880L (no)
WO (1) WO1994027632A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6410596A (en) * 1995-07-31 1997-02-26 Centre De Recherche De L'hopital Sainte-Justine Cytidine deaminase cdna as a positive selectable marker for ene transfer, gene therapy and protein synthesis
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US8207142B2 (en) 2001-07-31 2012-06-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibitor of DNA methylation
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
JO2778B1 (en) * 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
TWI477508B (zh) 2009-04-06 2015-03-21 Otsuka Pharma Co Ltd 用以治療癌症之組成物及方法
EP2416781B1 (en) 2009-04-06 2017-03-08 Otsuka Pharmaceutical Co., Ltd. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
UY32546A (es) 2009-04-06 2010-10-29 Eisai Inc Composiciones y metodos para tratar cancer
HUE042327T2 (hu) 2011-08-30 2019-06-28 Astex Pharmaceuticals Inc Decitabin-származék készítmények
WO2017004538A1 (en) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
BR112020002280A2 (pt) 2017-08-03 2020-07-28 Otsuka Pharmaceutical Co., Ltd. composto farmacológico e métodos purificação do mesmo

Also Published As

Publication number Publication date
EP0703787A1 (en) 1996-04-03
GB9311252D0 (en) 1993-07-21
JPH08510385A (ja) 1996-11-05
WO1994027632A1 (en) 1994-12-08
AU6803694A (en) 1994-12-20
NO954880D0 (no) 1995-11-30

Similar Documents

Publication Publication Date Title
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
NO985376L (no) Kinolinkarboksamider som TNF-inhibitorer og som PDA-IV inhibitorer
AU5811001A (en) Cxcr4 antagonist treatment of hematopoietic cells
AU9536898A (en) 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the holesterin-ester transfer protein
NO326660B1 (no) Imidazolyl-cykliske acetal forbindelser, farmasøytiske sammensetninger inneholdende disse forbindelser og anvendelse av forbindelsene
ES8801930A1 (es) Procedimiento para la preparacion de dipeptidos de n,n'-dialquilguanidino
TR199801360T2 (xx) Yeni ikameli imidazol bile�imleri.
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
DK545584A (da) Enzym-resistente immonumodulatoriske peptider
DE69914357D1 (de) Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
FI953748A0 (fi) Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina
IL162836A (en) Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments and pharmaceutical compositions thereof
TR199802676A2 (xx) T�m�rlerin, t�m�rle ilgili hastal�klar�n ve ka�eksinin tedavisi ve �nlenmesi i�in y�ntem.
ATE203991T1 (de) Inhibitoren der protein-kinase c
BR0109062A (pt) Inibidores de frutose-1,6-bisfosfatase de arila
ATE354372T1 (de) Verwendung von mif-antagonisten zur krebstherapie
DK1007537T3 (da) Receptor-protein med betegnelsen 2F1
DK0910647T3 (da) Human DNase i hyperaktive varianter
AU7548500A (en) Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents
ATE331791T1 (de) Phosphodiesterase 10
FR2662698B1 (no)
TR199802649A2 (xx) Sikline ba�l� kinazlar�n inhibit�rleri i�in ba�lama e�leri.
NO963029L (no) Anvendelse av IL-10 for å stimulere cytologisk aktivitet av enkjernete celler i perifert blod
PT1100528E (pt) Utilizacao de novos agentes indutores de morte celular em sinergia com os interferoes
DE69739167D1 (de) Zusammensetzungen zur modulierung der länge von telomeren